Biotech & Longevity
Where it stands
As of 20 July 2026
The science is moving steadily, but what reaches patients is being decided by portfolio math — programmes are changing hands faster than they are failing.
Forces in tension
four programmes cut or sold in a week — a phase 3 antibiotic went for $500k upfront
Ebola frontline staff unpaid while the vaccine trial was stood up in six weeks
focal prostate therapy has 10-year data and reaches about 1,000 of 15,000 eligible men a year
prediction markets opened on FDA decisions and trial read-outs this month
FDA released 14 drug rejection letters after a three-month pause, with more planned
a first-in-class cholesterol drug cleared as a pill rather than an injection
What to watch
Whether the assets big companies cut this month get picked up and finished elsewhere, or quietly sit.
This board is the synthesized picture of 8 recent Biotech & Longevity editions. It describes where things stand — the forces, not a forecast, and never advice on what to do.